drugset / Trial / NCT06143904

A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants

NCT06143904

Phase 1 Completed 10 enrolled Sanofi
Non-randomizedSequentialOpen-labelBasic science

Summary

Objectives: To determine pharmacokinetic (PK) variables, including absolute bioavailability (F), of Genz-99067, the free base of the L-tartaric acid salt of Genz-112638 as it exists in plasma, after a single intravenous (IV) dose and after a single oral dose of Genz-112638 (unlabeled). To determine the PK, total recovery, routes and rates of excretion, and the metabolic profile of Genz-99067 after 5 days of BID oral dosing with unlabeled Genz-112638 followed by a single dose of \[14C\]-Genz-112638.

Timeline

Start
2009-06-03
Primary completion
2009-07-05
Completion
2009-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Eliglustat Small molecule Intravenous